Skip to main content

Bruce H. Morimoto, PhD

Vice President, Drug Development at Allon Therapeutics Inc.

Location: Vancouver Canada

Dr. Morimoto is the vice president of Drug Development at Allon Therapeutics. His responsibilities include management of the clinical research, nonclinical and manufacturing activities for the davunetide drug development program in frontotemporal dementia, Alzheimer disease and schizophrenia.

Prior to joining Allon Therapeutics, Dr. Morimoto worked for MDS Pharma Services in their consulting group. Dr. Morimoto formerly directed the chronic/neuropathic pain program at NeuroMed Technologies (now Zalicus Pharmaceuticals). He also held positions at AMUR Pharmaceuticals and Phoenix International Life Sciences.

Dr. Morimoto received his BSc and PhD in biochemistry from the University of California, Los Angeles (UCLA), and after a post-doctoral fellowship at University of California, Berkeley, he joined the faculty in the Chemistry Department at Purdue University. Dr. Morimoto is a member of the Safety Pharmacology Society Board of Directors and part of the Orasi Medical Executive Advisory Board.

Associated Grants

  • Testing of Davunetide for Intranasal Administration in Pre-clinical Models Over Expressing Alpha-synuclein


  • Evaluation of the Neuroprotective Peptide NAPVSIPQ in Models of Parkinson's Disease


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.